A Guide to Physical and Occupational Therapy for CMT
This first-of-its-kind publication outlines the assessment and care of people with CMT. Based on research, experience and patient input, it will help ensure you get the best possible care for your specific needs.Read more ...
Three Major Patient Advocacy Groups Focused on CMT Research Collaborating on FDA “Voice of the Patient” Report
This CMT Awareness Month, the Charcot-Marie-Tooth Association (CMTA) is proud to join the Muscular Dystrophy Association (MDA) as a sponsor of the Hereditary Neuropathy Foundation (HNF) who will be hosting the Externally-led Patient-Focused Drug Development ...Read more ...
The Summer 2018 CMTA Report
The Summer 2018 CMTA Report PDF is now available. In addition to our regular features, you’ll find these articles and items of interest: STAR: The CMTA’s Plan for Finding Treatments and Cures for CMT CMTA Research Spotlight: Alliance ...Read more ...
Regenacy Pharmaceuticals Announces Collaboration with the CMTA to Advance Ricolinostat for the Treatment of Hereditary Neuropathy
Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced a collaboration with the CMTA to validate the role of HDAC6 in multiple forms of CMT disease and evaluate the efficacy of ricolinostat, a selective HDAC6 inhibitor.Read more ...
CMTA Announces Strategic Partnership with Acceleron to Advance CMT Treatment Options
The Charcot-Marie-Tooth Association (CMTA), a patient organization focused on supporting the development of innovative medicines for Charcot-Marie-Tooth (CMT) disease, today announced a strategic partnership with Acceleron Pharma, a Cambridge-based biopharmaceutical company dedicated to developing medicines ...Read more ...